September 1, 2010 - Saint Barnabas Medical Center Implements AutoPulse for High-Quality CPR

INVESTOR CONTACT:

A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655

MEDIA CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com

SAINT BARNABAS MEDICAL CENTER IMPLEMENTS ZOLL AUTOPULSE

One of First Hospitals in New Jersey to Institute the Devicefor High-Quality CPR

September 1, 2010CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that Saint Barnabas Medical Center, one of the largest non-profit, non-sectarian hospitals in New Jersey, has installed the AutoPulse® Non-Invasive Cardiac Support Pump for resuscitative capabilities in the hospital’s emergency department.

The AutoPulse is the only automated chest compression device that uses an easy-to-use, load-distributing LifeBand® to squeeze the entire chest in a truly uninterrupted “hands-free” manner even during transport of the patient from the ambulance to the operating room. As a result, victims receive more consistent, high-quality chest compressions than those delivered by other automated CPR devices, which means improved blood flow to the heart and brain during sudden cardiac arrest (SCA).  Additionally, it offers the benefit of freeing up clinicians to focus on other life-saving interventions.

“At Saint Barnabas Medical Center, we see over 84,000 emergency department patients each year.  The AutoPulse is extremely useful in Code Blue situations since it is easy to apply and fit to the patient. Most importantly, it can be used for substantial amounts of time to deliver steady, proper chest compressions without rescuer fatigue, something that cannot be achieved with manual CPR,” states Christopher Freer, M.D., Chairman of Emergency Medicine, Saint Barnabas Medical Center.

“We’re pleased that Saint Barnabas recognizes the value AutoPulse can provide in improving patient care and survival from sudden cardiac arrest. Being able to provide consistent, high-quality chest compressions during code situations, while freeing up clinical staff to attend to other critical needs, is vitally important, especially when every second counts,” said Jonathan A. Rennert, President of ZOLL.

While two other hospitals and a number of EMS services in New Jersey use the device for resuscitation, the largest user in the state is the Port Authority of New Jersey and New York. Over 5,000 AutoPulse devices are in use in hospital and emergency service organizations worldwide. 

About Sudden Cardiac Arrest  

SCA is an abrupt disruption of the heart’s function, causing a loss of blood flow to vital organs. It claims more than 325,000 lives each year in the U.S. It is the leading cause of unexpected death worldwide and often strikes without warning. Currently, only about 5 percent of victims survive; 95 percent will die from SCA. 

About Saint Barnabas Medical Center

Saint Barnabas Medical Center, the oldest and largest non-profit, non-sectarian hospital in New Jersey, is one of the busiest in the state with more than 84,000 Emergency Department patients and more than 35,000 in-patients annually. 

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly  Report on Form 10-Q  filed with the SEC on August 11, 2010. You should not place undue reliance on the forward looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2010 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, and LifeBand are registered trademarks of ZOLL Medical Corporation.